Bevacizumab and Radiation Therapy for Sarcomas

• The dose of bevacizumab and radiation therapy will be the same for all participants throughout the study.
• Bevacizumab will be given as an intravenous infusion every 2 weeks for a total of 4 doses.
• Radiation therapy will begin 2 weeks after the first bevacizumab infusion and will be delivered 5 days per week over a period of 6 weeks. This is done as an outpatient procedure. Each 2 week period will be considered a separate treatment cycle. Participants will be treated with radiation therapy for a maximum of 3 cycles (6 weeks).
• A surgeon will evaluate the participants tumor by radiologic studies before study treatment to determine if surgical removal is possible. After the completion of study treatment, a surgeon will repeat the evaluation of the tumor. Surgery will performed 6-7 weeks after the completion of radiation therapy.

Inclusion criteria

• Primary soft tissue sarcoma (STS) or an isolated local recurrence of STS. Open incisional biopsy or core biopsies should be performed within 8 weeks prior to registration
• Tumor grade of intermediate or high grade
• Tumor must be located on the upper extremity, the lower extremity, trunk, retroperitoneum, or pelvis
• Primary tumors must be > 5.0cm in maximal diameter and local recurrence can be any size
• 18 years of age or older
• Zubrod performance status of 0-2
• Adequate organ and marrow function

Exclusion criteria

• Metastatic disease
• Pregnant or lactating women
• HIV positive patients
• Prior treatment with radiation, chemotherapy or biotherapy for this tumor
• History or evidence of central nervous system (CNS) disease
• Serious, non-healing wound, ulcer, or bone fracture
• Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year
• History of stroke within the past 6 months
• Major surgical procedure or significant traumatic injury within 28 days
• Current or recent (within 10 days) use of full-dose oral or parenteral anticoagulants or thrombolytic agents.
• Presence of bleeding diathesis or coagulopathy
• Proteinuria at baseline or clinically significant impairment of renal function
• History of abdominal fistula, gastrointestinal perforation, or inta-abdominal abscess within the past 6 months
• Documented history of uncontrolled seizures
• Grade 2 or greater sensory neuropathy based upon the NCI CTCAE, version 3.0
• Known history of deep vein thrombosis or pulmonary embolus
• Known hypercoagulable disorder
• History of hepatic cirrhosis or current hepatic dysfunction